“Green light” to Lilly’s monoclonal antibody to migraine

2018-11-28T17:21:25+00:0028/11/2018|Categories: Industry, News|Tags: , , , , , , , |

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes of migraine, blocks its function Administered with a month subcutaneous injection which can be applied to the patient with a pen or pre-filled syringe. In all three clinical trials, galcanezumab has shown significantly reducing the monthly average of migraine days and an improvement in functionality versus placebo. "Migraine is [...]

100 Million Neurons Found Outside The Brain

2018-08-20T13:09:10+00:0020/08/2018|Categories: News|Tags: , , , , , |

Trupti Gokani, MD is a neurologist and author of The Mysterious Mind. She practices a blend of Western and Eastern medicine which focuses on the root cause and holistic treatment of a patient, combined with functional neurology. Dr. Gokani told us about the significance of the gut-brain connection in her recent interview. As neurologists, Dr. Gokani says, we study the central nervous system. "We look at the brain that's in our head, the spinal cord, and the peripheral nervous system, which includes the autonomic, sympathetic, and parasympathetic nervous systems. We don't focus on that other system, which is the enteric [...]

Estrogen may explain why women suffer more often migraines

2018-08-16T14:40:12+00:0016/08/2018|Categories: News|Tags: , , |

Spanish researchers have discovered that the role of this sex hormone around the trigeminal nerve could be key in migraine episodes, which could explain why woman suffer from them more often.  Sex hormones could play a key role in the onset of migraine episodes, according to a study published today by the team of Antonio Ferrer Montiel, a researcher at the Miguel Hernández University. In a paper published in the journal Frontiers in Molecular Biosciences, the authors demonstrate the role of estrogen - a hormone that presents its highest levels in women of reproductive age - in the cells surrounding [...]

New Aimovig Medication Approved

2018-07-31T13:40:17+00:0031/07/2018|Categories: Industry, News|Tags: , , , |

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its- kind treatment specifically designed for migraine prevention Jul 30, 2018 Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia. It works by blocking a receptor called the calcitonin gene-related peptide receptor (CGRP-R) which plays a critical role in mediating the incapacitating pain of migraine. [...]

Why are migraine patients skipping effective behavioral treatments?

2018-06-06T17:50:13+00:0006/06/2018|Categories: News|Tags: , , , |

Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine. Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred despite the fact that these treatments are considered first-line, safe and effective treatments by medical guidelines. Those who were referred but did not seek treatment most commonly cited lack of time, cost concerns, and skepticism the treatments will work, according to the new study published [...]

This is how a medicine is manufactured (from the laboratory to the pharmacy)

2018-06-06T12:40:24+00:0006/06/2018|Categories: Industry, News|Tags: , , |

Ten years and a billion euros. This is the time and average cost for a drug to complete the process that goes from its initial discovery to being sold at a pharmacy. Considering this data, it´s not difficult to imagine the manufacture of a drug as an obstacle course in which only a few molecules reach the goal. The researchers of the Center for Biological Research of the CSIC María del Carmen Fernández and Nuria E. Campillo narrate in their book "How a medicine is made. From the laboratory to the pharmacy " how long and expensive this process is. [...]

Novartis’ Migraine prevention therapy is closer to being approved

2018-06-04T13:44:50+00:0004/06/2018|Categories: Industry, News|Tags: , , , |

Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes of years of disability worldwide. Aimovig is the first treatment of its kind specifically developed to prevent migraine, blocking the peptide related to the calcitonin gene (CGRPR), which plays an essential role in the pathology of migraine. If approved, Aimovig will be administered once a month [...]

We and our partners use cookies, to collect browsing data to give you the best online experience and to personalize the content, play multimedia content, interact with social networks and perform browsing analytics. If you continue browsing we understand you accept the use of such technology. For more information visit our cookies policy Find out more

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close